ChromaDex Corporation (CDXC)
NASDAQ: CDXC · IEX Real-Time Price · USD
1.60
-0.05 (-3.03%)
Mar 27, 2023, 4:00 PM EDT - Market closed
Stock Price Forecast
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ChromaDex stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '22 | Nov '22 | Dec '22 | Jan '23 | Feb '23 | Mar '23 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 6 | 6 | 6 | 6 | 6 | 6 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 12 | 12 | 12 | 12 | 12 | 12 |
Financial Forecast
Revenue This Year
87.41M
from 72.05M
Increased by
21.32%
Revenue Next Year
105.08M
from 87.41M
Increased by
20.22%
EPS This Year
-0.12
from -0.24
EPS Next Year
-0.05
from -0.12
Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Revenue | 31.56M | 46.29M | 59.26M | 67.45M | 72.05M | 87.41M | 105.08M | 129.95M |
Revenue Growth | 48.85% | 46.69% | 28.01% | 13.82% | 6.82% | 21.32% | 20.22% | 23.67% |
EPS | -0.61 | -0.56 | -0.33 | -0.40 | -0.24 | -0.12 | -0.05 | 0.06 |
EPS Growth | - | - | - | - | - | - | - | - |
No. Analysts | - | - | - | - | - | 8 | 5 | 5 |
Revenue Forecast
Revenue | 2023 | 2024 | 2025 |
---|---|---|---|
High | 94.5M | 110.2M | 141.2M |
Avg | 87.4M | 105.1M | 130.0M |
Low | 82.8M | 98.8M | 119.2M |
Revenue Growth
Revenue Growth | 2023 | 2024 | 2025 |
---|---|---|---|
High | 31.2%
| 26.0%
| 34.4%
|
Avg | 21.3%
| 20.2%
| 23.7%
|
Low | 14.9%
| 13.0%
| 13.4%
|
EPS Forecast
EPS | 2023 | 2024 | 2025 |
---|---|---|---|
High | 0.04 | 0.03 | 0.18 |
Avg | -0.12 | -0.05 | 0.06 |
Low | -0.23 | -0.10 | - |
EPS Growth
EPS Growth | 2023 | 2024 | 2025 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price target, rating and forecast data provided by Finnhub and sourced from Wall Street analysts and other sell-side and buy-side analysts and investors. Data disclaimer.